Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6RFLE)

Drug Name

ML364 Drug Info

Synonyms

1991986-30-1; 2-[(4-methylphenyl)sulfonylamino]-n-(4-phenyl-1,3-thiazol-2-yl)-4-(trifluoromethyl)benzamide; NCGC00262995-02; CHEMBL3392741; SCHEMBL20782884; BCP20769; EX-A4472; ML-364; s6748; AKOS032944928; ZINC169341604; CS-6197; NCGC00262995-01; AS-55828; HY-100900; 2-((4-methylphenyl)sulfonamido)-N-(4-phenylthiazol-2-yl)-4-(trifluoromethyl)benzamide; 2-(4-Methylphenylsulfonamido)-N-(4-phenylthiazol-2-yl)-4-(trifluoromethyl)benzamide

Indication

Disease Entry	ICD 11	Status	REF
Inflammation	1A00-CA43.1	Preclinical	[1]

Cross-matching ID

PubChem CID: 70789348
TTD Drug ID: DM6RFLE

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ubiquitin carboxyl-terminal hydrolase 2 (USP2)	TTUEQ1W	UBP2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018 Jan;17(1):57-78.
2	The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer. Cell Death Differ. 2020 Sep;27(9):2710-2725.